Integrated Report

Overview

The report presents Kobayashi Pharmaceutical's FY2019 consolidated performance, including net sales of ¥168.0 billion. It sets a Group-wide 54.6% reduction target for Scope 1 and 2 CO2 emissions by 2030 from 2017 levels. The ESG section describes a structured materiality process approved by the Board and reports the establishment of a dedicated ESG department in 2020, alongside work-style and women's advancement initiatives.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2019
Period: 1 January 2019 – 31 December 2019
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

SBTi status
CDP score

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services